Nextcure announces first patient dosed in the phase 1 study of lncb74 (b7-h4 adc) as therapeutic for treating multiple cancers

Beltsville, md., jan. 10, 2025 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced the first patient has been dosed in its phase 1 study of lncb74, a b7-h4-targeting antibody-drug conjugate (adc) as a therapeutic for treating multiple cancers.
NXTC Ratings Summary
NXTC Quant Ranking